Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma. 1988

P Y Holoye, and D T Carr, and H M Dhingra, and B S Glisson, and J S Lee, and W K Murphy, and T Umsawasdi, and D Jeffries
Department of Medical Oncology, University of Texas M.D. Anderson Hospital and Tumor Institute, Houston 77030.

Fourteen evaluable patients with small cell bronchogenic carcinoma received tiazofurin, an inhibitor of inosine monophosphate dehydrogenase, that progressed after one combination chemotherapy. No objective remission was observed at the dosage of 800 mg/m2 for 5 consecutive days. Toxicity was moderate.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002283 Carcinoma, Bronchogenic Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA. Carcinoma, Bronchial,Bronchial Carcinoma,Bronchial Carcinomas,Bronchogenic Carcinoma,Bronchogenic Carcinomas,Carcinomas, Bronchial,Carcinomas, Bronchogenic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

P Y Holoye, and D T Carr, and H M Dhingra, and B S Glisson, and J S Lee, and W K Murphy, and T Umsawasdi, and D Jeffries
October 1985, Cancer research,
P Y Holoye, and D T Carr, and H M Dhingra, and B S Glisson, and J S Lee, and W K Murphy, and T Umsawasdi, and D Jeffries
January 1990, Investigational new drugs,
P Y Holoye, and D T Carr, and H M Dhingra, and B S Glisson, and J S Lee, and W K Murphy, and T Umsawasdi, and D Jeffries
January 1985, Investigational new drugs,
P Y Holoye, and D T Carr, and H M Dhingra, and B S Glisson, and J S Lee, and W K Murphy, and T Umsawasdi, and D Jeffries
January 1986, Cancer chemotherapy and pharmacology,
P Y Holoye, and D T Carr, and H M Dhingra, and B S Glisson, and J S Lee, and W K Murphy, and T Umsawasdi, and D Jeffries
April 1992, Investigational new drugs,
P Y Holoye, and D T Carr, and H M Dhingra, and B S Glisson, and J S Lee, and W K Murphy, and T Umsawasdi, and D Jeffries
May 1978, European journal of cancer,
P Y Holoye, and D T Carr, and H M Dhingra, and B S Glisson, and J S Lee, and W K Murphy, and T Umsawasdi, and D Jeffries
June 1985, Cancer research,
P Y Holoye, and D T Carr, and H M Dhingra, and B S Glisson, and J S Lee, and W K Murphy, and T Umsawasdi, and D Jeffries
January 1986, Investigational new drugs,
P Y Holoye, and D T Carr, and H M Dhingra, and B S Glisson, and J S Lee, and W K Murphy, and T Umsawasdi, and D Jeffries
April 1969, Cancer chemotherapy reports,
P Y Holoye, and D T Carr, and H M Dhingra, and B S Glisson, and J S Lee, and W K Murphy, and T Umsawasdi, and D Jeffries
April 1983, American journal of clinical oncology,
Copied contents to your clipboard!